Free Trial
NASDAQ:OBSV

ObsEva (OBSV) Stock Price, News & Analysis

ObsEva logo

About ObsEva Stock (NASDAQ:OBSV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
208 shs
Average Volume
8.94 million shs
Market Capitalization
$7.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Stock News Headlines

StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
ObsEva Announces Update on Board of Directors
ObsEva SA OBSN
ObsEva SA OBSEF
See More Headlines

OBSV Stock Analysis - Frequently Asked Questions

ObsEva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.23.

ObsEva (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ObsEva investors own include NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Allena Pharmaceuticals (ALNA), Bionano Genomics (BNGO) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/04/2021
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OBSV
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20.11 million
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
N/A

Miscellaneous

Free Float
66,743,000
Market Cap
$7.94 million
Optionable
Not Optionable
Beta
0.68

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:OBSV) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners